|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value.
|
17451198 |
2007 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The in situ expression of 10 genes was assessed by the immunohistochemical approach at the protein level: CDH1, CDH13, COX2, cyclin A1, hMLH1, MGMT, p14(ARF), p73, RAR- , and TIMP3 genes in the context of the methylation status in colorectal cancer.
|
15526363 |
2004 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we examine CpG island methylation of 10 genes (hMLH1, BRCA1, APC, LKB1, CDH1, p16(INK4a), p14(ARF), MGMT, GSTP1 and RARbeta2) and 5-methylcytosine DNA content, in inherited (n = 342) and non-inherited (n = 215) breast and colorectal cancers.
|
11751682 |
2001 |
|
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability.
|
11221863 |
2001 |
|
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Extensive methylation of MGMT promoter was primarily present in CRCs while partial methylation was common in APs.
|
18240147 |
2008 |
|
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Its combination with hypermethylated in cancer 1 (HIC1), death-associated protein kinase (DAPK) and O-6-methylguanine DNA methyltransferase (MGMT), allowed the detection of aberrant methylation in 98% of colorectal carcinomas and 100% of gastric carcinomas.
|
15068392 |
2003 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to evaluate the activity of temozolomide in terms of response rate in patients with metastatic CRC and MGMT methylation, after failure of approved treatments.
|
24379162 |
2014 |
|
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Detection of NAT2 genotypes and MGMT promoter methylation may be useful in the risk assessment for CRC in Taiwanese women.
|
19107910 |
2009 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alkylating agents, such as dacarbazine, exert their antitumor activity by DNA methylation at the O(6)-guanine site, inducing base pair mismatch; therefore, activity of dacarbazine could be enhanced in CRCs lacking MGMT.
|
23422094 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
BRAF mutations are common in sporadic colorectal cancers (CRCs) with a DNA mismatch repair (MMR) deficiency that results from promoter methylation of hMLH1, whereas KRAS mutations are common in MMR proficient CRCs associated with promoter methylation of MGMT.
|
15542810 |
2004 |
|
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Nineteen percent of the screened population (137/740) had confirmed tissue and/or serum MGMT promoter methylation, including 25% (57 of 229) for CRC, 36% (55 of 154) for esophageal cancer, 11% (12 of 113) for head and neck cancer, and 5% (13 of 242) for non-small cell lung carcinoma.
|
23443801 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite a well-established role of MGMT aberrations in carcinogenesis, neither MGMT promoter methylation nor MGMT loss serves as a prognostic biomarker in colorectal cancer.
|
21140203 |
2011 |
|
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
To identify which CpG sites are critical for its downregulation, we analyzed the methylation status of the MGMT gene promoter in two sites in CRC patients.
|
23271133 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The frequency of MGMT promoter hypermethylation in UC-associated CRCs found in this study (16.7%) is obviously lower than previously reported in sporadic CRCs (39.0-42.0%).
|
12920593 |
2003 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the common Leu84Phe and Ile143Val polymorphisms in MGMT influence risk of colorectal cancer in women possibly through modulating estrogen receptor-dependent transcriptional activation, which has previously been shown to occur in response to DNA alkylation damage.
|
16633920 |
2006 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings paralleled immunohistochemical patterns of hMLH1 and MGMT protein loss in an independent series of 231 colorectal cancers and were consistent with current epigenetic profiles of colorectal cancer subsets.
|
19060925 |
2009 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Methylated secreted frizzled-related protein gene 2 (SFRP2), hyperplastic polyposis protein gene (HPP1) and O6-methylguanine-DNA methyltransferase gene (MGMT) in stools from 52 patients with CRC, 35 patients with benign colorectal diseases and 24 normal individuals were analyzed using methylation-specific PCR.
|
17352030 |
2007 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Detailed methylation patterns and protein expression profiles of MGMT in colorectal carcinoma surgical margins.
|
18028895 |
2008 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mean total MGMT level varied between tumor types: 554 +/- 404 fmol/mg protein (+/-SD) for prostate cancer, 87.4 +/- 40.3 fmol/mg protein for CNS tumors, and 244 +/- 181 fmol/mg protein for colorectal cancer.
|
20068091 |
2010 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The methylation specific PCR (MSP) assay was used for determining the methylation status of CpG island of p16 and MGMT genes in CRC patients.
|
31004929 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In line with these studies, MGMT was linked to the formation of human sporadic CRC.
|
23929436 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The methylation frequencies of MGMT gene promoter were 41.4%, 34.2%, and 44.2% in stomach, esophageal, and colorectal cancer cases while as 16.6, 13.3, and 13.3 in respective controls.
|
28135856 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We have recently demonstrated that the MGMT gene is silenced by promoter methylation in many human tumors, including colorectal carcinomas.
|
10811111 |
2000 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Methylation of the CpG island in the MGMT promoter region is a frequent event in several cancer types including colorectal cancer, lung cancer, lymphoma, and glioblastoma.
|
19789298 |
2009 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, this meta-analysis suggests that the PARP-1 rs1136410: T > C polymorphism is a susceptibility factor for GI cancers, but the variant allele of MGMT rs12917: C > T polymorphism appears to be a protective factor for colorectal cancer.
|
24203816 |
2014 |